Differentiation of Primate Pluripotent Stem Cells to Hematopoietic Lineage Cells
First Claim
Patent Images
1. A method of differentiating primate pluripotent stem cells into immature dendritic cells comprising contacting the primate pluripotent stem cells with a plurality of exogenous cytokines comprising granulocyte-macrophage colony stimulating factor (GM-CSF) and bone morphogenic protein 4 (BMP-4).
2 Assignments
0 Petitions
Accused Products
Abstract
The invention provides methods of differentiating primate pluripotent stem cells into cells of hematopoietic lineage. The invention further provides hematopoietic lineage cells differentiated from primate pluripotent stem cells, as well as methods of using the same and kits comprising the same.
27 Citations
20 Claims
- 1. A method of differentiating primate pluripotent stem cells into immature dendritic cells comprising contacting the primate pluripotent stem cells with a plurality of exogenous cytokines comprising granulocyte-macrophage colony stimulating factor (GM-CSF) and bone morphogenic protein 4 (BMP-4).
-
14. A method of differentiating primate pluripotent stem cells into immature dendritic cells comprising:
-
a) contacting the pPS cells with bone morphogenic protein 4 (BMP-4), vascular endothelial growth factor (VEGF) and stem cell factor (SCF) to differentiate the primate pluripotent stem cells into mesoderm; b) contacting the mesoderm of a) with vascular endothelial growth factor (VEGF), stem cell factor (SCF), and GM-CSF to differentiate the mesoderm into hematopoietic stem cells; c) contacting the hematopoietic stem cells of b) with SCF and granulocyte macrophage colony stimulating factor (GM-CSF) to differentiate the hematopoietic stem cells into monocytes; and d) contacting the monocytes with granulocyte macrophage colony stimulating factor (GM-CSF) and interleukin 4 (IL-4) to differentiate the monocytes into immature dendritic cells.
-
-
15. A method of differentiating in vitro a cell expressing stage specific embryonic antigen 3 (SSEA3), stage specific embryonic antigen 4 (SSEA4) and markers detectable using antibodies designated Tra-1-60, and Tra-1-81 into a cell expressing CD11c comprising contacting the cell expressing stage specific embryonic antigen 3 (SSEA3), stage specific embryonic antigen 4 (SSEA4) and markers detectable using antibodies designated Tra-1-60, and Tra-1-81 with a differentiation cocktail comprising:
- GM-CSF and BMP-4.
- View Dependent Claims (16, 17)
- 18. A system for the production of mitotically inactive antigen presenting cells comprising a) a first isolated cell population comprising pPS cells and b) a second isolated cell population comprising mitotically inactivated mature dendritic cells which are the in vitro progeny of a portion of the first isolated cell population.
Specification